The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines

被引：0
|
作者：
Li, Fang [1 ]
Growney, Joseph [1 ]
Battalagine, Linda [1 ]
Qiu, Shumei [1 ]
Manley, Paul [2 ]
Monahan, John [1 ]
机构：
[1] Novartis, Cambridge, MA USA
[2] Novartis, Basel, Switzerland
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2239
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
    Herrera, Vivian Arrias
    Zeindl-Eberhart, Evelyn
    Jung, Andreas
    Huber, Rudolf Maria
    Bergner, Albrecht
    ANTICANCER RESEARCH, 2011, 31 (03) : 849 - 854
  • [2] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [3] Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
    Kirstein, Martha M.
    Boukouris, Aristeidis E.
    Pothiraju, Deepika
    Buitrago-Molina, Laura E.
    Marhenke, Silke
    Schuett, Jutta
    Orlik, Johanna
    Kuehnel, Florian
    Hegermann, Jan
    Manns, Michael P.
    Vogel, Arndt
    LIVER INTERNATIONAL, 2013, 33 (05) : 780 - 793
  • [4] Radiosensitization by the Dual PI3K/mTOR inhibitor NVP-BEZ235
    Cerniglia, George J.
    Karar, Jayashree
    Koumenis, Constantinos
    Maity, Amit
    CANCER RESEARCH, 2012, 72
  • [5] Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S84 - S85
  • [6] Radiation Sensitization of HNSCC Cells by the dual PI3K / mTOR Inhibitor BEZ235 as a function of the Cell Cycle
    Brandt, F. W.
    Balzer, V
    Dreffke, K.
    Wittig, A.
    Dikomey, E.
    Arenz, A.
    Schoetz, U.
    Engenhart-Cabillic, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S165 - S165
  • [7] Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
    Meng, Wei
    Wang, Baocheng
    Mao, Weiwei
    Wang, Jiajia
    Zhao, Yang
    Li, Qifeng
    Zhang, Chenran
    Ma, Jie
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2019, 81 (01): : 93 - 102
  • [8] Comparison of anti-proliferation activity of BEZ 235, a multi-step inhibitor of mTOR pathway, vs. BKM120, a pan PI3K inhibitor, in lung cancer cell lines (LCCL)
    Huang, Chao H.
    Beaudoin, Christopher
    Van Veldhuizen, Peter
    Farassati, Faris
    CANCER RESEARCH, 2014, 74 (19)
  • [9] The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
    Gan, Zhen Ying
    Fitter, Stephen
    Vandyke, Kate
    To, Luen B.
    Zannettino, Andrew C. W.
    Martin, Sally K.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (04) : 343 - 354
  • [10] Assessment of response to treatment with the PI3K/mTOR inhibitor BEZ235 with FLT PET in a tumor xenograft model
    Wanek, T.
    Fuereder, T.
    Pflegerl, P.
    Jaeger-Lansky, A.
    Hoeflmayer, D.
    Strommer, S.
    Mueller, M.
    Langer, O.
    Kuntner, C.
    Wacheck, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S298 - S299
12345